News

June 2026 digest

S. aureus and Eczema Herpeticum: A Laboratory Paradox, a Bedside Emergency Eczema herpeticum, or Kaposi-Juliusberg syndrome caused by HSV-1, is one of the situations in atopic dermatitis where clinical hesitation can be dangerous. Dermatologists who have seen severe cases remember the picture well: sudden painful monomorphic vesicles or punched-out erosions on eczematous skin, fever, facial […]

Read More

#StayInformed: June 2026 PubMed picks

Can inflamed AD skin become a gateway for topical biologics?➜ DOI: 10.34133/bmr.0368Why it matters:A thermosensitive hyaluronic acid/Pluronic hydrogel delivered mesenchymal stromal cell-derived extracellular vesicles through AD-like lesional skin in mice, improving dermatitis scores, epidermal thickening, mast-cell infiltration, cytokine expression, barrier markers, and oxidative stress.Context and caution:The most intriguing point is that damaged AD skin allowed EV [...] Read More

Bridging Care and Science in the Heart of the Amazon

Dr. Roberto TAKAOKA’s visit to Manaus launches a vital new support network while opening doors to unique environmental research on atopic dermatitis. Last month, Dr Roberto TAKAOKA, Vice-President of ISAD, visited Manaus in the heart of Brazil’s Amazon region as part of a project by the Brazilian Atopic Dermatitis Association (AADA) to establish new support […]

Read More

May 2026 digest

From “Response” to “Reassurance” Topical corticosteroids (TCS) remain the cornerstone of atopic dermatitis (AD) management worldwide. Yet, despite decades of clinical use, a paradox persists: while clinicians rely on TCS as first-line therapy, many patients remain uncertain, and sometimes fearful, about how to use them safely over time. This tension is increasingly visible in discussions […]

Read More

ISAD × Umer Doctor

New Strategic Partnership The International Society of Atopic Dermatitis (ISAD) is proud to announce a new exclusive strategic partnership with Umer Doctor, China’s premier professional platform for dermatologists. This collaboration marks a significant milestone as we prepare for the 16th Georg RAJKA International Symposium on Atopic Dermatitis, taking place in Beijing. Why This Partnership Matters […]

Read More

#StayInformed: May 2026 PubMed picks

Fast runners or long-distance champions? Rethinking AD therapy trajectories➜ DOI: 10.1111/all.70395A new Allergy editorial proposes an athletic metaphor for AD therapies: JAK inhibitors as “sprinters,” IL-4/IL-13 biologics as “mid-distance runners,” and emerging immune-resetting approaches as “marathoners.” An attractive framework—but perhaps the key question is not only how therapies run, but how disease evolves in each patient. [...] Read More

April 2026 digest

Pediatric Atopic Dermatitis Guidelines in 2026:Convergence of Evidence, Divergence of Practice The recent JAAD 2026 guidelines on pediatric atopic dermatitis DOI: 10.1016/j.jaad.2026.02.114, led by the late Robert Sidbury, marks an important milestone: it is the first fully evidence-graded, pediatric-specific update in the era of biologics and JAK inhibitors. Built on a strict GRADE methodology and largely restricted […]

Read More

#StayInformed: April 2026 PubMed picks

AI-Powered Atopic Dermatitis Assessment: Patients Can Contribute + Small punch biopsies and non-negative matrix factorization (NMF) to study AD transcriptome + An important role of IL-22 in Th2 driven acute AD in epidermal reconstructs models + Health-Related Quality of Life in AD and Psoriasis: Are There Distinct Psychological Traits? + Towards a scientific approach of traditional Chinese medicine formulas

Read More